Revenue grew quickly, but margin dilution is the key question
The headline number was strong: H1 revenue reached EUR552.5 million, up 16% reported. But the more important question was profit quality. Fagron's adjusted EBITDA margin fell to 19.4%, down 60 basis points year over year. That leaves investors weighing two possibilities: whether the company is accepting lower margins to secure growth, or whether it is simply working through a transitional period that could improve in the second half.
Organic growth looks reasonable; margin pressure is the issue
Fagron still posted 3.1% organic growth at CER, and 7% when normalizing the GLP-1 effect. That suggests the underlying business is still expanding. Adjusted EBITDA also rose to EUR107 million, so profitability did not break.
The problem is margin dilution. Gross margin decreased by 218 basis points, driven by acquisitions and a change in North America Pacific product mix. In other words, Fagron grew sales, but a smaller share of each euro is landing in EBITDA for now.
Quick Backtesting Tool
If this is temporary transition noise, the second half could restore the margin profile. If it proves more persistent, Fagron will need to show that growth is becoming more profitable, not just larger.
LATAM strength and integration support the longer-term case
The group-level margin slip looks less concerning when you break down performance by region. LATAM is showing both growth and margin expansion, EMEA is still growing with margin improvement, and the balance sheet remains within internal limits.
LATAM is the clearest source of high-quality growth
Latin America is the strongest proof point that Fagron can grow and expand margins at the same time. The region produced EUR120.5 million of revenue, up 38.7%, with 8% organic growth at CER and an adjusted EBITDA margin expansion of 120 basis points to 18.6%.
Management also described outstanding growth this quarter in LATAM, mainly driven by brands in Brazil, with additional contributions from Prepharma and Vipacum. If that momentum holds, LATAM can offset weaker comparison math in other regions.
Integration is visible, but not fully proven yet
Recent deals contributed EUR68.7 million to group revenues, and management said previously announced acquisitions are progressing as planned. In EMEA, the core business also held up well, with 4.1% organic growth at CER and an adjusted EBITDA margin expansion of 30 basis points.
That does not mean integration is fully settled. Operating expenses rose 10% year over year due to recent acquisitions, even though they declined to 230 basis points as a percentage of revenue. For now, the better reading is that integration is underway, with some cost absorption still to come.
The balance sheet still allows room for execution
Net debt to EBITDA Ratio: 2.1 times, up from 1.8 times at the end of FY2025, but still below the internal threshold of 2.8 times. That leaves Fagron with some financial flexibility as it absorbs acquisitions and supports regional growth.
The next update needs to show whether H2 is genuinely stronger
The positive read still works, but it depends on execution. Management has already said H2 should be stronger than H1, which gives the company room to recover the year, but also means the next report matters more than the first-half headline.
Where the story can still weaken
First, mix matters. The group posted 7% when normalizing the GLP-1 effect versus 3.1% organic growth at CER. That helps the optimistic view, but it also means part of the growth story depends on a temporary comparator effect easing.
North America Pacific is the clearest watchpoint. The segment generated EUR213.2 million of revenue, but only 0.4% reported growth and 0.2% organic growth at CER. Its adjusted EBITDA margin was 17%, below the group average, so any weakness there can weigh on the whole portfolio.
Second, acquisition integration still needs to translate into clearer profitability. Expenses rose in absolute terms, even if they improved as a percentage of revenue. That is normal in a transition, but investors should watch whether margins start to recover rather than simply stabilize.
What matters in the next report
Management also maintained a full-year profitability view circa 20%. Combined with the comment that H2 should be stronger than H1, that makes the next update a meaningful test of whether Fagron can convert top-line growth back into healthier margins.
